For overweight or obese individuals without diabetes, but with pre-existing cardiovascular disease, semaglutide (Ozempic, ...

Injectable GLP-1 agonists help people struggling to lose weight. Patients are finding the drug also helps reduce recurring ...

For overweight or obese individuals without diabetes, but with pre-existing cardiovascular disease, semaglutide (Ozempic, ...

For overweight or obese individuals without diabetes, but with pre-existing cardiovascular disease, semaglutide (Ozempic, Wegovy) is not cost-effective at current pricing, new research shows.

In a notable move, Hims & Hers Health donated $1 million to President-elect Donald Trump’s inauguration fund, signaling its ...

Medicare’s drug pricing negotiations — the first of their kind in the United States, passed under President Joe Biden — face ...

Weight management platform Found is today launching oral semaglutide dissolvable tablets for individuals looking for ...

Madrigal Pharmaceuticals' strong launch is confirmed with impressive sales in Q1 and Q2. Learn why MDGL stock could benefit ...

New in vivo preclinical data announced today, demonstrate that icovamenib, in combination with semaglutide showed additional 11.5% body weight ...

Novo Nordisk initiated study validates the power of proteomics to provide unique insights into mechanisms of action and ...

Ready to crush your New Year’s health goals? These breakthrough medications offer more than weight loss—they support your ...

Biomea Fusion (BMEA) announce compelling results from in vivo studies of icovamenib in combination with semaglutide. Highlights of the Study: ...